SCT 650A
Alternative Names: SCT-650ALatest Information Update: 01 Apr 2021
At a glance
- Originator Sinocelltech
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ankylosing spondylitis; Psoriasis
Most Recent Events
- 22 Feb 2021 Preclinical trials in Ankylosing spondylitis in China (unspecified route) before February 2021 (SinoCellTech pipeline, February 2021)
- 22 Feb 2021 Preclinical trials in Psoriasis in China (Parenteral) before February 2021 (SinoCellTech pipeline, February 2021)